BioSpace News Archive

X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company

Bausch+Ströbel vial filler with SKAN Isolator technology, and VarioSys® syringe and vial filler set to arrive in early 2022

Orphan drug manufacturers struggle to uncover valuable commercial insights from their data management efforts, according to a new industry report from Beghou Consulting.

Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that etesevimab (JS016 or LY-CoV016) 2800 mg and bamlanivimab (LY-CoV555) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, “events”) in high-risk patients recently diagnosed with COVID-19,

The digital genome market is set to observe exponential growth on account of rising prevalence of severe chronic and genetic disorders around the world.

SITES and Mach Medical’s new advanced manufacturing headquarters recently opened in Columbia City, Ind., and began production of its orthopedic medical devices, which are the company’s signature products as the No. 2 life sciences producer in the United States

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to its Board of Directors, effective January 21, 2021.

The blood and blood components market expansion would be augmented by the high prevalence of bleeding disorders and the surge in the number of surgeries globally.

The breast cancer therapeutics market is forecasted to experience substantial growth on account of growing prevalence of breast cancer across developed economies around the world.

Mednet, a clinical research technology company, announced new and expanded benefits of the Mednet Value Program, first launched in 2019.